Revolution Medicines, Inc. reiterated full year 2022 GAAP net loss to be between $260 million and $290 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.53 USD | +0.29% | +2.64% | +34.34% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.34% | 6.36B | |
+21.85% | 46.44B | |
+38.08% | 39.1B | |
-8.05% | 38.76B | |
+29.04% | 31.24B | |
-13.75% | 25.8B | |
+10.65% | 25.9B | |
+38.43% | 13.12B | |
-6.92% | 11.32B | |
-12.29% | 10.68B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2022